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Emerging evidence supports the dual function of 
kinase suppressor of Ras 1 (KSR1) as an active kinase 
and a scaffold, although it has been extensively referred 
as a pseudokinase, due to the absence of key residues in 
its catalytic domain [1, 2]. As a scaffolding protein, KSR1 
orchestrates the assembly of the protein kinases RAF, 
mitogen activated protein kinase (MAPK) kinase (MEK), 
and extracellular signal-regulated kinase (ERK) in the 
canonical Ras-RAF-MAPKs pathway, in a Ras-dependent 
manner or upon growth factor treatment [1, 3]. Conversely, 
structural and biochemical studies reveal that KSR1 is 
capable of phosphorylating MEK and more importantly, 
the catalytic activity of KSR is markedly increased when 
BRAF or inhibitor-bound CRAF is introduced in the 
complexes [1, 4, 5]. Such findings add complexity to the 
ERK spatio-temporal pathway control and identify KSR1 
as a modulator of these pathways.
In light of its regulatory role in oncogenic Ras-
RAF-MAPKs signaling, extensive efforts have attempted 
to establish KSR1 as an oncogene in Ras-dependent 
cancers. Indeed, KSR1 has been shown to contribute to 
oncogenesis in various forms of Ras-activated cancer, 
including skin, pancreatic and lung carcinomas [1]. First, 
absence of KSR1 inhibits tumor formation in different 
Ras-mediated mouse models (KSR1-/-), suggesting that 
KSR1 is required for Ras-transduced MAPK activated 
tumorigenesis. Moreover, depletion of KSR1 reduces 
tumor growth of K-Ras-dependent pancreatic and lung 
cancer xenografts in nude mice, further supporting KSR1 
as an oncogene as well as a potential therapeutic target.
However, our own studies reveal an interesting, and 
yet unexpected role of KSR1 in breast cancer, where Ras 
mutations are rare. Using tumor tissue microarrays in a 
large patient cohort with a long term follow-up, we observe 
that breast cancer patients with high KSR1 had better 
disease free- and overall survival, results also supported 
by Oncomine analyses, microarray data and genomic data 
from paired tumor and cell-free DNA (cfDNA) samples 
revealing loss of heterozygosity [6]. KSR1 expression 
is positively associated with breast cancer 1, early onset 
(BRCA1), BRCA1-associated ring domain 1 (BARD1) 
and checkpoint kinase 1 (Chk1) levels in breast cancer 
specimens. Intriguingly, phospho-profiling of major 
components of the canonical Ras-RAF-MAPKs pathway, 
including RAF, MEK and ERK, show no significant 
changes upon KSR1 overexpression or depletion. These 
results underline its role beyond coordinating MAPKs 
signaling and challenge its oncogenic function in breast 
cancer.
Further experiments support a tumor suppressive 
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Figure 1: KSR1-regulated signaling in cancer. A. In Ras-dependent cancers, KSR1 coordinates the classical oncogenic Ras-RAF-
MAPKs signaling to promote tumor. B. In breast cancer, on one hand, KSR1 represses p53 transcriptional activity through modulation of 
deleted in breast cancer 1 (DBC1) phosphorylation and the SIRT1-DBC1 complex. More importantly, KSR1 affects BRCA1 expression by 
decreasing BRCA1 ubiquitination partly through regulating BARD1 protein abundance and the BRCA1-BARD1 interaction
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role of KSR1. Of note, breast cancer cells overexpressing 
KSR1 form fewer and smaller size colonies compared 
to the parental ones, while an in vivo mouse model 
also demonstrates that the growth of xenograft tumors 
overexpressing KSR1 is inhibited. It appears that the 
tumor inhibitory effect of KSR1 is BRCA1-dependent 
as shown by in vitro 3D-matrigel and soft-agar assays. 
Consistent with the correlation between KSR1 and 
BRCA1 in clinical samples, in vitro assays demonstrate 
KSR1 overexpression increases BRCA1 protein levels 
by decreasing BRCA1 ubiquitination partly through 
elevating BARD1 protein abundance and the BRCA1-
BARD1 interaction. These findings integrate KSR1 into a 
complicated signaling network involving BRCA1-BARD1 
complex. Unquestionably, alternative mechanisms 
underlying BRCA1′s up-regulation by KSR1 other than 
through BARD1 remain to be examined.
Our current understanding of KSR1′s function in 
breast cancer is far from complete (Figure 1). Puzzlingly, 
in addition to executing its anti-tumor effects through 
BRCA1, KSR1 negatively regulates transcriptional 
activity of p53 by reducing p53 acetylation via modulation 
of deleted in breast cancer 1 (DBC1) phosphorylation [7]. 
How can KSR1 up-regulates BRCA1 and inhibits p53 
activity at the same time? What determines its preferable 
binding partners and thus contributes to its inhibitory 
outcome? An interesting and simple theory might be 
the following: since DBC1 is a positive regulator of p53 
activity and a repressor for BRCA1, it potentially positions 
KSR1 into a dynamic state connecting p53 and BRCA1. 
Ultimately, while BRCA1 compensates for the loss of 
p53 activity, KSR1 tilts the balance scale towards tumor 
suppression in cancer cells. Further investigation is much 
needed to address the underlying mechanisms. In addition, 
evidence regarding other aspects of its action are evolving: 
a very recent study characterizing the proteomic profile of 
KSR1-regulated signaling in response to genotoxic agents 
in breast cancer illustrates a broad functional network 
conferred by KSR1, highlighting its importance in the 
chemotherapy response [8]..
A better understanding of the molecular 
determinants of the distinctive behaviour of KSR1 
in different types of cancer is essential to the optimal 
targeting of this dual functional kinase-scaffold protein. 
Our studies suggest the tumor suppressive action of KSR1 
and its clinical relevance in patient stratification, placing 
KSR1 in the major oncoprotein pathways.
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